It was very gratifying to see that the patients who were in the trial, and we sort of had a hint that they were on study drug and not on placebo when patients who were previously uncontrolled for their CAH on glucocorticoids began to show reductions in their androstenedione. So once a patient in the trial, a subject was able to reduce their androstenedione level on a fixed dose of glucocorticoid, which had been maintained for a designated period of time before study trial entry, then we could ask the question, could we maintain those lower levels of androstenedione while at the same time with the crinecerfont on board, or in the placebo case, reduce the level of glucocorticoid. So that was another study objective that again proved to be a valid suspicion that this was an achievable goal of using this adjunctive therapy to treat our patients.